[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Region Stockholm\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":659},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,55,0,25,[9,45,72,93,113,144,176,201,228,256,284,304,339,363,388,407,425,452,477,502,526,552,582,607,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631689","cognitive-behavior-therapy-in-psychiatric-inpatient-care-100631689",false,"NCT07503951","Cognitive Behavior Therapy in Psychiatric Inpatient Care","Implementing Brief Cognitive Behavior Therapy in Psychiatric Inpatient Care Delivered by Mental Health Professionals","Inclusion Criteria:\n\n* Admitted as patient in Psychiatric Inpatient Care\n* Expected to remain admitted on the ward for at least 3 days\n* Assessed as being capable of giving consent regarding participation.\n* Assessed as able to engage in and complete conversations.\n* Sufficient level of language skills to understand the content of conversations and client material included in the intervention.\n\nExclusion Criteria:\n\n• Other ongoing psychotherapeutic contact.","ALL",{"count":19,"type":20},204,"ESTIMATED","INTERVENTIONAL",[23],"NA","The current project aims to evaluate the extent to which psychological interventions based on Cognitive Behavioral Therapy (CBT), provided within the framework of care, may be helpful for patients in psychiatric inpatient care. The background to the project is the substantial lack of psychological treatment available to patients in psychiatric inpatient care, despite evidence suggesting that active psychological interventions can have a positive effect on psychiatric problems, such as reduced depressive symptoms, decreased anxiety, and reduced rates of readmission to inpatient psychiatric care. Previous research evaluating the effects of CBT in inpatient settings is, however, rare and more knowledge is needed both nationally and internationally. In addition to the potential direct effect of psychological treatment on patients' difficulties, there is also a high demand for such support from patients, for example, as expressed at patient forums conducted by participation coordinators in Region Stockholm, Sweden. In psychiatric outpatient and primary care, there is currently good evidence supporting CBT, and these methods are highly beneficial for both patients and practitioners. Digitalization and blended formats, with therapist-supported internet treatments, can also increase access to interventions. Studies of CBT for, for example, depression, anxiety, and psychosis are well documented and have shown a significant reduction in psychiatric symptoms as well as improved quality of life. But scarcity of studies conducted in inpatient care limits available knowledge on feasibility and effects of CBT interventions to this group of patients. This strongly motivates further systematic evaluation and research on CBT in inpatient psychiatric care, and the aim of the present study is to implement and evaluate CBT in this context. Investigators plan to test this at four to six psychiatric inpatient units and evaluate the impact of the intervention on patients' levels of activity and symptoms of low mood and depression in a randomized controlled trial. In addition, investigators wish to conduct two different interview studies with patients and staff to obtain a detailed description of how they experience the intervention.",[26,27],"Depression, Anxiety Disorders","Psychiatric Inpatients",[29,30,31],"Cognitive Behavioral Therapy","Inpatient Psychiatric Care","Mental Health Professionals","RECRUITING","2026-06-02",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":36},"2026-04-01",{"date":40,"type":20},"2028-03-31",{"name":42,"class":43},"Region Stockholm","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100626329","a-group-based-psychoeducational-intervention-for-partners-of-child-sexual-abuse-material-offenders-100626329","NCT07434219","A Group Based Psychoeducational Intervention for Partners of Child Sexual Abuse Material Offenders.","A Group Based Psychoeducational Intervention for Partners of Child Sexual Abuse Material Offenders: A Non-Randomized Feasibility Study","Inclusion Criteria:\n\n* Female partners of male CSAM offenders\n* A score of ≥ 3 points on the General Health Questionnaire 12 (GHQ-12) at screening and an affirmative response to the follow-up question: Do you feel that your reduced psychological well-being is primarily related to your partner's CSAM offenses?\n* Ability to understand spoken and written Swedish\n* Willingness to participate in the intervention\n* Signed written informed consent form.\n\nExclusion Criteria:\n\n* The partner has committed hands-on sexual offenses against children\n* Presence of a severe mental disorder (e.g., psychosis or major depression) requiring immediate treatment 8) Psychological or cognitive conditions that could compromise participant safety or study integrity (e.g., intellectual disability).","FEMALE","18 Years",{"count":55,"type":20},20,[23],"The overall aim of this feasibility study is to investigate the clinical characteristics of female partners of male child sexual abuse material (CSAM) offenders and to evaluate the feasibility of a novel psychoeducational group intervention designed to address their specific needs.\n\nThe main questions it aims to answer are:\n\n1. What are the clinical characteristics of female partners of male CSAM offenders?\n2. Is a psychoeducational group intervention for female partners of male CSAM offenders feasible?\n3. Does a psychoeducational group intervention for female partners of male CSAM offenders provide any indication of effectiveness?\n\nFeasibility will be assessed in terms of 1) recruitment, time from recruitment to offered intervention and completed sessions 2) expectancy of treatment improvement, credibility, and satisfaction 3) acceptability and relevance 4) occurrence of negative effects 5) changes in depression- and anxiety symptoms and psychological well-being 6) changes in daily functioning.",[59],"Partner",[61,62,63],"intervension","partner","pedophilia","NOT_YET_RECRUITING",{"date":66,"type":36},"2026-06-04",{"date":68,"type":20},"2026-06-15",{"date":70,"type":20},"2029-03-01",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100547185","psychological-treatment-for-paraphilic-disorders-100547185","NCT06404684","Psychological Treatment for Paraphilic Disorders","Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: the Evaluation of an Adapted Cognitive Behavioral Therapy (CBT) Manual for Paraphilic Disorders","Inclusion Criteria:\n\n1. Participants included in the study Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: a Case-control Study\n2. Deemed to benefit from CBT.\n3. Signed informed consent form for participation in the CBT treatment.\n\nExclusion Criteria:\n\n1. Mental condition that could negatively influence either the patient's health or the scientific aspects of the study, e.g., substance use syndrome, other ongoing psychotherapeutic treatment.\n2. Initiation of medication or change change of concurrent medication or dosage in the past three months regarding antidepressants, attention deficit hyperactivity disorder medication, cortisone, testosterone, naltrexone, testosterone blockers, or dopamine precursors. Smaller adjustments may in some cases be acceptable (assessed by study psychiatrist).",{"count":80,"type":20},14,[23],"The goal of this randomized study is to learn if a psychological intervention can treat help-seeking patients with paraphilic disorders.\n\nThe main questions it aims to answer are:\n\n1. Is psychological therapy helpful for the reduction of problematic sexual behaviors among patients with paraphilic disorders?\n2. Is psychological helpful for the reduction of psychiatric symptoms and risk factors for sexual violence and improving quality of life among patients with paraphilic disorders?\n3. How do patients with paraphilic disorders describe pathways to care (e.g. perceived obstacles to seeking care) and how do they experience the treatment?\n\nThe treatment addresses specific sexual problems. It also addresses mental symptoms (e.g. depression and anxiety). A psychologist provides the treatment face to face (on site or video). The aim is to finish the treatment within 12 weeks.\n\nThe patient will report symptoms on a daily basis. The patient will also be interviewed after completion of treatment. The investigator will pose questions such as \"Was there anything that was experienced as particularly helpful in the treatment?\", \"Was there anything that was not helpful?\". The investigator will also ask about treatment seeking behavior with questions such as \"What kinds of resources would be helpful if they were available?\"",[84],"Paraphilic Disorders",[86],"paraphilic disorders",{"date":66,"type":36},{"date":89,"type":36},"2025-03-04",{"date":91,"type":20},"2028-01",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":44},"100505466","paraphilic-disorders-and-other-conditions-with-risk-for-sexual-violence-a-case-control-study-100505466","NCT05861752","Paraphilic Disorders and Other Conditions With Risk for Sexual Violence: a Case-control Study","Inclusion Criteria:\n\n1. 18 years of age and older\n2. Signed informed consent\n3. Be able to understand the Swedish language in oral and in writing\n4. Meet criteria for paraphilia (sexual deviation) according to DSM-5 (with the exception of pedophilia), compulsive sexual behavior disorder according to the International Classification of Diseases (ICD-11), or sexsomnia (sexual act during sleep)\n\nExclusion Criteria:\n\n1. Serious mental disorder such as current psychosis or severe depression that requires immediate handling\u002Ftreatment.\n2. Psychological condition that may endanger the patient's health or the scientific parts of the study, this is assessed by the assessing physician and psychologist (for example, intellectual disability).\n\nCriteria for control persons:\n\nInclusion criteria\n\n1. Age and sex matched to clinical population\n2. Signed informed consent\n3. Be able to understand the Swedish language in oral and in writing\n\nExclusion criteria\n\n1. Serious somatic illness (determined by the study physician).\n2. Ongoing substance use syndrome\n3. Serious psychiatric illnesses\u002Fconditions that require medical attention (determined by the study physician).\n4. First-degree relative with schizophrenia, bipolar disorder or deceased by suicide.\n5. Positive screening for compulsive sexual behavior disorder, paraphilia or sexsomnia.",true,{"count":101,"type":20},240,"OBSERVATIONAL","The goal of this case-control study is to compare clinical characteristics in help-seeking individuals with paraphilic disorders or sexsomnia (sexual behaviors during sleep- a diagnosis in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5)), as compared to healthy controls. The main questions this study aims to answer are:\n\n(1a) Is there a difference in experience of violence between the clinical population and healthy controls? Is there a difference between the clinical groups?\n\n(1b) What are the clinical characteristics of these conditions (psychiatric, sociodemographic, and genetic\u002Fepigenetic factors)? Does the clinical population differ from healthy controls?\n\n(1c) How are the psychometric properties of the assessment forms (primarily those addressing sexual deviance and compulsive sexuality) in the project?\n\n(1d) How has sexual interest developed over time among patients with paraphilic disorders? (including the person's own description of e.g. triggers and expectations).\n\nFollow-up of clinical population:\n\n(2) What is the typical treatment as usual (TAU) for the patient population? (e.g., average length of care, the percentage of dropouts and what kind of treatment has been given) (3) Are there any factors at baseline (e.g., presence of neuropsychiatric symptoms, age, symptom burden) that predict treatment outcome? (i.e., symptom burden based on self-assessments at follow-up 3, 6 and 12 months from the start of treatment and records in offence registers after 10 years).",[84,105,106],"Sexual Addiction","Parasomnia",{"date":66,"type":36},{"date":109,"type":36},"2022-10-19",{"date":111,"type":20},"2037-10-19",{"name":42,"class":43},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":121,"minAge":53,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100639912","phase-2-prostate-androgen-response-investigation-using-a-stratification-biomarker-predicting-prostate-cancer-downstaging-by-neoadjuvant-darolutamide-with-pcai-immunoscore-100639912","NCT07617272","Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore","PARIS-BIO - Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore in a Non-randomised Open Label Prospective Trial","PARIS-BIO","Inclusion Criteria:\n\n* Biopsy-confirmed high-risk prostate cancer defined as: Global ISUP score \\> 3 with any MRI PI-RADS score OR Global ISUP score = 3 with MRI PI-RADS score = 5\n* Candidate for radical prostatectomy\n* Clinical prostate MRI not older than 3 months at screening\n* ECOG performance status score of 0 or 1\n* Able to receive Darolutamide for 90-120 days\n* Signed informed consent form\n* Willingness to use contraception if sexually active\n\nExclusion Criteria:\n\n* Metastatic (M1) or node-positive (N2) disease\n* Prior treatment with androgen receptor antagonists\n* Prior treatment with gonadotropin-releasing hormone (GnRH)\n* History of prior systemic or local therapy for prostate cancer (including radiation and focal therapy)\n* Major surgery \\\u003C4 weeks prior to inclusion","MALE",{"count":123,"type":20},100,[125],"PHASE2","The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer. Patients will receive Darolutamide monotherapy for 90-120 days prior to radical prostatectomy. The study aims to validate if the biomarker can identify patients who achieve Minimal Residual Disease (MRD) at the time of surgery.",[128],"Prostate Cancer (Adenocarcinoma)",[130,131,132,133,134],"Prostate cancer","Neoadjuvant","Darolutamide","ARPI","Prediction of treatment response","2026-05-24",{"date":137,"type":36},"2026-06-01",{"date":139,"type":36},"2025-11-09",{"date":141,"type":20},"2030-12",{"name":42,"class":43},2,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":44},"100640925","peripheral-pulse-assessment-and-arterial-pressure-pulsar-100640925","NCT07609095","Peripheral pULSe Assessment and Arterial pRessure (PULSAR)","Association Between Palpable Peripheral Pulses and Arterial Blood Pressure in Patients With Circulatory Shock: An International Prospective Multicenter Observational Cohort Study","PULSAR","Inclusion Criteria:\n\n* Clinical signs of circulatory shock or impending circulatory failure\n* Availability of non-invasive and\u002For invasive arterial blood pressure monitoring\n* Pulse palpation possible without interfering with emergency care\n\nExclusion Criteria:\n\n* Peripheral vascular conditions preventing reliable pulse palpation\n* Major extremity amputation affecting assessment sites\n* Clinical situations where study procedures interfere with life-saving treatment",{"count":153,"type":20},5000,"This prospective multicenter observational study aims to investigate the relationship between palpable peripheral pulses and simultaneously measured arterial blood pressure in adult patients with circulatory shock or impending circulatory failure. Peripheral pulse palpation is routinely used in emergency medicine, trauma care, critical care, and cardiopulmonary resuscitation as a rapid clinical assessment of circulation. However, the association between palpable pulses and actual arterial blood pressure remains poorly validated.\n\nPatients treated in emergency departments, intensive care units, operating rooms, and other acute care settings will undergo routine pulse palpation at predefined anatomical locations including carotid, femoral, and radial arteries. Simultaneously measured non-invasive and\u002For invasive arterial blood pressure values will be recorded from routine clinical monitoring systems. Additional clinical variables relevant to circulatory status will also be collected.\n\nThe study seeks to define blood pressure thresholds associated with pulse palpability and evaluate the agreement between invasive and non-invasive blood pressure measurements in patients with circulatory shock.",[156,157,158,159,160],"Circulatory Shock","Hemodynamic Instability","Hypotension","Shock","Critical Illness",[156,162,163,164,165,158,166,167,168,157],"Hemodynamic Monitoring","Pulse Palpation","Peripheral Pulse","Arterial Blood Pressure","Critical Care","Trauma","Resuscitation","2026-05-19",{"date":171,"type":36},"2026-05-27",{"date":137,"type":20},{"date":174,"type":20},"2031-12-31",{"name":42,"class":43},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":44},"100628675","postoperative-high-flow-nasal-oxygenation-after-high-risk-surgery-in-the-frail-adult-100628675","NCT07464730","Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult","Hi-POP","Inclusion Criteria:\n\nAdults (≥18 years old) scheduled for elective abdominal (laparotomy or laparoscopy), open abdominal vascular or non-cardiac thoracic surgery under general anaesthesia with an estimated duration over 3 hours.\n\nAND\n\nMeeting at least two of the following criteria:\n\n* Age \\> 65 years\n* BMI \\>30\n* Preoperative SpO2 \\\u003C95 %\n* Scheduled for lobectomy or pulmonary segment resection\n* Respiratory tract infection the last month\n* Preoperative anaemia (Hb \\\u003C100) or severe hypoalbuminemia (\\\u003C20 g\u002FL)\n* Current smoker or previous smoker with \\>30 packyears\n* Pulmonary disease or OSAS\n* Heart failure\n* Clinical frailty (CFS 4)\n\nExclusion Criteria:\n\n* Not suitable for postoperative HFNO, as decided by a study member or the anaesthetist in charge (such as total nasal obstruction, skull fracture, facial injuries)\n* Pregnancy\n* Not able to understand the study information or sign an informed consent.\n* Not able to participate with the treatment postoperatively\n* Planned for delayed extubation in the intensive care\n* Preoperative non-invasive ventilation due to respiratory failure or a higher level of care than a regular ward",{"count":184,"type":20},200,[23],"High flow nasal oxygen (HFNO) in the immediate postoperative period has been demonstrated to reduce the risk of postoperative pulmonary complications (PPC) after cardiothoracic surgery. In specific groups of patients such as the obese and after upper abdominal surgery the results are contradictive. However, there is lack of evidence if HFNO in the general high-risk patient after abdominal and non-cardiac thoracic surgery can reduce the prevalence of PPC, hypoxaemia and escalation of therapy. Therefore, the investigators aim to compare the use of HFNO with conventional oxygen therapy (COT) in high-risk patients after abdominal and non-cardiac thoracic surgery regarding postoperative pulmonary complications.",[188],"Postoperative Pulmonary Complications (PPCs)",[190,191,192],"HFNO","High flow nasal oxygen","Postoperative pulmonary complication","2026-05-11",{"date":195,"type":36},"2026-05-14",{"date":197,"type":36},"2026-04-20",{"date":199,"type":20},"2029-03-09",{"name":42,"class":43},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100636787","innovative-non-invasive-diagnostics-and-personalized-treatment-strategies-for-endometriosis-through-advanced-multi-omics-and-ultrasound-integration-100636787","NCT07570225","Innovative Non-Invasive Diagnostics and Personalized Treatment Strategies for Endometriosis Through Advanced Multi-Omics and Ultrasound Integration","Innovativa Icke-invasiva Diagnostiska Och Personliga Behandlingsstrategier för Endometrios Genom Avancerad Multi-omik Och Ultraljudsintegration","ENDO-NOVA","Inclusion Criteria:\n\n* Women aged 18-45\n* Understands and speaks the Swedish language\n* Suspected or confirmed endometriosis\n\nExclusion Criteria:\n\n* Do not have a uterus","45 Years",{"count":211,"type":20},365,"Endometriosis is a prevalent gynecological condition affecting approximately 10% of women of reproductive age worldwide. It presents with nonspecific but often severe symptoms, including chronic pelvic pain (in 70% of cases) and infertility (in up to 40% of cases), imposing significant physical, psychological, economic, and societal burdens. Despite its widespread occurrence, the exact etiology and pathogenesis of endometriosis remain unclear, and no definitive cure exists. Early diagnosis and management are crucial for improving patient outcomes; however, major diagnostic delays persist. Current imaging techniques such as transvaginal ultrasound (TVUS) examination and magnetic resonance imaging, along with biochemical markers lack sufficient specificity. Consequently, confirmation of diagnosis still requires surgical procedures under general anesthesia, i.e.\n\nlaparoscopy (\"key-hole surgery\") and tissue biopsy. This delay exacerbates the disease burden and healthcare costs, underscoring the urgent need for non-invasive, precise diagnostic strategies. This project proposes a multi-modal approach integrating advanced ultrasound imaging with novel biomarkers identified via comprehensive multi-omics analyses, including proteomics, transcriptomics, and immune profiling, of patient-derived endometrial organoids. It aims to understand the underlying mechanisms of reduced endometrial receptivity of embryos in patients with endometriosis. Additionally, we will explore personalized treatment strategies by utilizing patient-specific organoids for drug screening and evaluation of treatment response.\n\nThis project aims to develop a non-invasive diagnostic strategy by integrating:\n\n1. AI-enhanced TVUS for improved lesion detection.\n2. Multi-omics biomarker discovery through proteomics, transcriptomics, and immune profiling.\n3. Underpinning the mechanisms of reduced endometrial receptivity in endometriosis using an in vitro model of embryo-endometrium interaction.\n4. Endometrial organoid models to enable precision medicine-based drug testing. The development of a reliable noninvasive or minimally invasive diagnostic test-or a combination of tests-could revolutionize the diagnostic pathway by reducing delays, avoiding the need for surgery, and facilitating disease monitoring and treatment evaluation.",[214,215],"Endometriosis","Infertility, Female",[217,218,219,220],"Transvaginal ultrasound","AI","Multi-omics","Organoid","2026-04-29",{"date":223,"type":36},"2026-05-06",{"date":197,"type":20},{"date":226,"type":20},"2029-04-20",{"name":42,"class":43},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":243,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":44},"100599844","virtual-versus-dye-based-chromoendoscopy-in-inflammatory-bowel-disease-surveillance-colonoscopy-100599844","NCT07089771","Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy","Inclusion Criteria:\n\n* Age ≥ 18 years and one of the criteria beneath:\n* Extensive ulcerative colitis or indeterminate colitis (IBD-U), or Crohn's colitis involving at least one-third of the colon, with a disease history of at least 8 years\n* IBD or IBD-U with primary sclerosing cholangitis (PSC)\n* IBD or IBD-U with a family history of colorectal cancer in a first-degree relative\n\nExclusion Criteria:\n\n* History of colorectal cancer or prior colectomy\n* Contraindications to dye use\n* Colonoscopies for therapeutic purposes\n* Pregnancy\n* Inability to consent",{"count":235,"type":20},480,[23],"People with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease affecting the colon, have a higher risk of developing colon cancer over time. To catch early signs of cancer, regular colonoscopies are recommended. In this study, the investigators are comparing two advanced methods of examining the colon during these surveillance colonoscopies. One method uses a special dye sprayed inside the colon to highlight abnormal areas (called dye-based chromoendoscopy). The other method uses new technology built into the camera to enhance the view without needing any dye (called virtual chromoendoscopy). Both methods use modern, high-definition equipment.\n\nThe purpose of this study is to find out if the newer, dye-free method is as good as the traditional dye method at detecting pre-cancerous changes (called dysplasia) in people with IBD.\n\nAdults with IBD who are due for a routine surveillance colonoscopy may be invited to take part. Participants will be randomly assigned to one of the two methods. No additional procedures are involved, and only the way the colon is viewed differs. The investigators will also look at how long the procedures take, how many biopsies are needed, any complications, and how patients experience the exam. Participants will be followed over time using national health records to check for long-term outcomes.\n\nThis research will help doctors better understand which method is most effective and comfortable for patients, and may guide future recommendations for cancer screening in people with IBD.",[239,240,241,242],"Inflammatory Bowel Disease (IBD)","Ulcerative Colitis (Disorder)","Crohns Disease","Colorectal Neoplasms",[244,245,246,247],"virtual chromoendoscopy","dye-based chromoendoscopy","dysplasia detection","IBD surveillance colonoscopy","2026-03-18",{"date":250,"type":36},"2026-03-20",{"date":252,"type":20},"2026-05-01",{"date":254,"type":20},"2032-12-31",{"name":42,"class":43},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":44},"100619197","ct-angiography-versus-angiogram-as-ancillary-tests-in-the-determination-of-death-by-neurologic-criteria-100619197","NCT07341490","CT-Angiography Versus Angiogram as Ancillary Tests in the Determination of Death by Neurologic Criteria","A Comparison of Computed Tomography-Angiography Versus Four-vessel Angiography in the Determination of Brain Death","Tadaa","Inclusion Criteria:\n\n* Adults 18 years or older\n* Ongoing critical care due to severe acute brain injury\n* Four vessel angiography necessary for the determination of complete cerebral infarction, according to Swedish legislation\n\nExclusion Criteria:\n\n* Treatment with extracorporeal membrane oxygenation (ECMO)\n* Radiologic examination by computed tomography deemed too challenging due to respiratory or circulatory instability, as determined by responsible clinician",{"count":265,"type":20},50,"Diagnostic performance of a novel protocol for computed tomography-angiography, as ancillary test in the determination of complete cerebral infarction, in comparison to four vessel angiography.",[268],"Infarction, Brain",[270,271,272,273,274,275],"Cerebral infarction","Cerebral angiography","CT angiography","Brain Death","Diagnostic performance","Brain infarct","2026-03-15",{"date":278,"type":36},"2026-03-17",{"date":280,"type":36},"2026-01-01",{"date":282,"type":20},"2028-12-31",{"name":42,"class":43},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":99,"sex":17,"minAge":53,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":44},"100560389","immunological-mechanisms-in-sarcoidosis-100560389","NCT06576505","Immunological Mechanisms in Sarcoidosis","Immunologiska Mekanismer Vid Sarkoidos","Inclusion Criteria:\n\n* Suspicion of sarcoidosis\n* Swedish speaking\n* Able to understand and approve of study protocol\n* No contraindications for planned interventions\n* For inclusion of healthy controls they need to be healthy and the same criteria as listed above for patients.\n\nExclusion Criteria:\n\n* No suspicion of sarcoidosis\n* Not Swedish-speaking\n* Not able to understand study protocol\n* Not approving of study protocol\n* Contraindications for planned interventions","90 Years",{"count":153,"type":20},"There is no cure for the inflammatory disease sarcoidosis. Virtually any part of the body can be affected but most often the lungs and lymph nodes. Outcomes after diagnosis vary widely among sarcoidosis patients, with some experiencing resolving disease and others developing chronic disease and lung fibrosis. Cardiac sarcoidosis can lead to life threatening arrythmias and calcium metabolism disturbances can lead to renal impairment.\n\nTreatment with different forms of immunosuppressants are usually tried to dampen symptoms but are not effective in all patients. Furthermore, the disease usually flares up after cessation of treatment. The variability in diseae course and treatment response is thought, at least to some degree, to be explained by individual differences in genetics, immune cells and signaling pathways. But existing evidence is limited. In other inflammatory diseases the gut microbiome is of importance for disease course but its role in sarcoidosis has not been clarified.\n\nIn this prospective project the investigators will study genes, inflammatory cells and signaling molecules in the lung, upper airways and blood, and to some extent microbes, also in faeces. Healthy volunteers will be included for comparative studies. Most samples will be taken during normal diagnostic work-up and follow-up of patients with\u002Fwith suspected sarcoidosis. The findings will be correlated to disease course and effects of different treatments. By linking to national health data and demographic registries, comorbidities and environmental factors will be correlated to data.\n\nBy this, the investigators hope to improve understanding of which genes, cells and signaling molecules that are of importance for resolving vs non-resolving disease and why some patients respond to a certain treatment and others don´t. The overall goal is to assess and predict sarcoidosis outcomes. We hypothesize that blood-based biomarkers including those taken during routine care as well as novel cell, signaling molecules and genetic markers, in combination with clinical characteristics can be used to predict outcomes, also treatment response, in sarcoidosis. The results can lead to tailored treatment and individual follow-up for each patient with sarcoidosis.",[295],"Sarcoidosis","2026-03-05",{"date":298,"type":36},"2026-03-06",{"date":300,"type":36},"2024-07-07",{"date":302,"type":20},"2034-12-31",{"name":42,"class":43},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":44},"100510836","liberal-or-restricted-fluid-intake-in-patients-with-heart-failure-100510836","NCT05931614","Liberal or Restricted Fluid Intake in Patients With Heart Failure","Liberal or Restricted Fluid Intake in Patients With Heart Failure: a Non-inferiority Randomized Controlled Trial","FLUID-HF","Inclusion Criteria:\n\n* Diagnosed with left ventricual heart failure (HFrEF, HFmEF)\n* Physical, cognitive and linguistic ability to carry out all aspects of the study\n\nExclusion Criteria:\n\n* Reversible cause of HF (thyroid disorders, severe anemia, etc.)\n* Hyponatremia at baseline (sodium \\\u003C130 mmol\u002FL)\n* eGFR at baseline \\\u003C30mL\u002Fmin\u002F1.73m2\n* Scheduled cardiac surgery, coronary intervention (percutaneous coronary intervention or coronary artery bypass graft surgery) within 3 months\n* Myocardial infarction within 3 months\n* Comorbidity for which fluid restriction or unlimited fluid intake is advised\n* Life expectancy \\\u003C6 months",{"count":313,"type":20},326,[23],"Heart failure is the most common cause of admission to hospital and is associated with high morbidity and mortality. Treatment options consist of medical- and device treatment and self-care strategies, where fluid restriction has been one of the components in the self-care management of patients with chronic heart failure. The medical treatment has progressed and improved over the years and considerably over the last few years, which has decreased symptoms and improved physical function of these patients. Despite our great success in the medical treatment of heart failure, we still face challenges in hospital readmissions and treatment strategies. It contributes to the increased need of evidence on, if and how, fluid intake and fluid restriction should be used as a self-care method. Fluid restriction as a self-care treatment is still commonly recommended in heart failure management although the scientific clinical evidence is lacking. Fluid restriction is associated with a higher degree of thirst and lower rated quality of life, and there is no consensus on how fluid restriction should be used, no plan for individualized treatment and no agreement on how fluid restriction should be a part of the patient self-care treatment. There is therefore a need for knowledge on how heart failure patients are affected by fluid restriction regarding clincal signs and symptoms of heart failure, quality of life, physical function, readmission to hospital or heart failure events. The primary aim of the study is to investigate whether a free fluid intake is safe compared to a restricted fluid intake, regarding clinical signs of heart failure measured as the presence of B-lines and\u002For an increase in NT-proBNP. The secondary aim is to clarify whether an unlimited fluid intake can improve quality of life and reduce thirst without affecting heart failure symptoms, physical activity, hospital readmissions and\u002For heart failure events.",[317],"Heart Failure",[319,320,321,322,323,324,325,326,327,328,329,330],"Quality of life","Intervention","Thirst distress","Symptoms","Physical capacity","Hospital readmissions","Lung ultrasound","Fluid intake","B-lines","NT-ProBNP","Heart failure","Fluid restriction","2026-02-20",{"date":333,"type":36},"2026-02-24",{"date":335,"type":36},"2024-02-14",{"date":337,"type":20},"2028-12",{"name":42,"class":43},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":44},"100539478","braining---evaluation-of-acute-effects-of-physical-exercise-100539478","NCT06304363","Braining - Evaluation of Acute Effects of Physical Exercise","Braining Study - Physical Exercise in Psychiatry - Evaluation of Acute Effects","Inclusion Criteria:\n\n* Included in the retrospective study Physical Exercise as Adjunctive Therapy for Affective Disorder and Anxiety and has given informed consent to participation in a Braining booster session.\n\nExclusion Criteria:\n\n* Severe psychiatric disorder such as mania and psychosis\n* Medical conditions such as heart- and lung diseases where PE is contraindicated.\n* Unable to understand written and spoken Swedish language.",{"count":347,"type":20},30,[23],"\"Braining\" is a clinical method for physical exercise as adjunctive therapy in psychiatric care. The core components are personnel-led group training sessions and motivating contact with psychiatric staff, as well as measurements and evaluations before and after a training period.\n\nThe scientific purpose of this study is to investigate immediate and short-term effects of a booster-session of several Braining classes.",[351],"Psychiatric Disorder",[353,354],"Psychiatric disorder","Physical Exercise","2026-02-04",{"date":357,"type":36},"2026-02-06",{"date":359,"type":20},"2028-01-01",{"date":361,"type":20},"2029-12-31",{"name":42,"class":43},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":369,"targetDuration":371,"studyType":102,"phases":4,"briefSummary":372,"conditions":373,"keywords":376,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":44},"100536832","intimate-partner-violence-among-people-who-inject-drugs---prevalence-risk-factors-and-experiences-100536832","NCT06269952","Intimate Partner Violence Among People Who Inject Drugs - Prevalence, Risk Factors and Experiences","Inclusion Criteria: at least 18 years of age, injecting drugs, participating in the needle syringe program in Sweden\n\n\\-\n\nExclusion Criteria:\n\n* under the age of 18\n* heavily intoxicated\n* psychotic symptoms",{"count":370,"type":20},500,"1 Year","There are around 15,6 million people who inject drugs (PWID) worldwide, of which around 3,5 million are women who inject drugs (WWID) (1). In Sweden, estimates suggest 8000-21000 PWID (2). PWID are exposed to substantial health risks that are directly linked to injection drug use, such as blood borne viruses (hepatitis and HIV), overdoses and skin and tissue infections. Additionally psychiatric disorders are common and PWID's general health is often neglected (3,4,5).\n\nIn Sweden, harm reduction units such as needle and syringe programs (NSP) have scaled-up in recent years. In Stockholm the first NSP opened in 2013 and the second in 2018. In 2022, 4600 individuals were enrolled in the program since it opened, of which approximately 25% were women. Around 2000 were active participants, defined as having visited the program at least once during the last 12 months. In 2021 54% of the participants stated amphetamine as the last drug injected, 31% heroin, 4% buprenorphine and 11% other drugs. Most participants were between 30-49 years of age. In addition to distribution of sterile needles and injection paraphernalia, the NSP staff (nurses, doctors, midwifes, counselors) provides services such as testing for blood borne viruses, vaccinations, wound care, take-home naloxone, reproductive health services, counselling, support in contact with social service and referrals for substance use disorder treatment and hepatitis C\u002FHIV treatment.\n\nGender-based violence (GBV) is a global health issue and WHO estimates that one in three women globally have been exposed to some sort of partner violence during their lifespan (7). Intimate partner violence (IPV) is defined as violent behavior between two people who have a close relationship, such as partners, ex-partners, siblings, relatives, friends and alike. In Sweden around 14% of women and 5% of men are exposed to physical violence in an intimate partner relationship during their lifespan however 20-25% of women and around 17% of men are exposed to psychological violence during their lifespan (8; 9). The prevalence of IPV among PWID is estimated to be significantly higher than in the general population (10). A study from USA found the risk of IPV to be three times higher and the prevalence estimated between 35-57% (7). In international studies, IPV exposure is found to be a significant risk factor for needle sharing among WWID (11, 12). There are other well-known consequences of IPV including impact on sexual and reproductive health rights, physical and psychological wellbeing, increased risk of contracting HIV and hepatitis C (13; 14). IPV exposure disproportionately affects WWID worldwide, however studies in Sweden on IPV exposure in the PWID population is scarce. To date there are studies that address this among women with substance use disorders but none with an exclusive focus on PWID or WWID. In clinical research of women diagnosed with substance use disorders (SUD) with psychiatric comorbidities and social challenges, one study indicates that the majority (91%, n=79) of women had been exposed to some form of IPV (15). Another study of women with SUD (n=52), 50% reported exposure of serious violence and the majority (96%) reported exposure to psychological violence (10). There are different types of IPV; psychological, physical, sexual, financial, latent, digital, neglect, honor related, aftermath of IPV (16). Our research team has previously carried out a qualitative interview study among WWID at the Stockholm NSP in 2019 to investigate reasons and barriers for participation among women (17). The interviews illustrated that IPV is common. In the proposed studies, for this doctoral thesis, we have chosen to focus on physical, sexual, psychological and financial violence among PWID motivated by findings in our previous research.\n\nPWID and specifically WWID are regarded as groups who are especially vulnerable for IPV exposure and should therefore be prioritized in the national efforts to prevent IPV (15). However, there are no studies estimating the prevalence and frequency of IPV among PWID in Sweden. Previous international studies suggest that PWID are exposed to IPV to a greater extent than the general population, and women with substance use disorders are exposed to an alarming degree of violence (15). In Sweden there are no tailored interventions for PWID or WWID who are exposed to IPV, it is reasonable to believe that there is a need for a multi-faceted program for PWID exposed to IPV, however this is still unexplored.\n\nThe overall aim of this project is to increase knowledge about IPV among PWID and WWID as particularly vulnerable groups in regards to IPV. More specifically, the aim is to investigate the prevalence and frequency of different types of IPV among PWID at the Stockholm NSP and to explore the experiences' of IPV, needs and preferences for IPV support among WWID to facilitate tailored support and prevention programs for those exposed.",[374,375],"Intimate Partner Violence (IPV)","People Who Inject Drugs",[377,378,379],"intimate partner violence","domestic violence","people who inject drugs","2026-02-02",{"date":382,"type":36},"2026-02-05",{"date":384,"type":36},"2023-10-05",{"date":386,"type":20},"2026-07",{"name":42,"class":43},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":44},"100616464","evaluation-of-a-new-mri-technique-to-reduce-breathing-related-artifacts-in-brain-imaging-100616464","NCT07305948","Evaluation of a New MRI Technique to Reduce Breathing-Related Artifacts in Brain Imaging","Prospective Evaluation of a Free Induction Decay (FID) Navigator-Based Off-Resonance Correction Method (DORK) for Improving High-Resolution 3D Echo Planar (EPI) Susceptibility-Weighted (SWI) Brain MRI","DORK","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Undergoing a routine clinical brain MRI at Karolinska University Hospital\n* Able to understand the study information and provide written informed consent\n* Sequence parameters and scan protocol compatible with the research acquisition (3D-EPI SWI)\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* Standard contraindications to MRI (e.g., non-MRI safe implants, severe claustrophobia)\n* Clinical conditions requiring urgent imaging where research consent is not feasible\n* Significant motion or incomplete scans preventing creation of research images (rare)",{"count":123,"type":20},"This study aims to improve the quality of brain magnetic resonance imaging (MRI) scans by testing a new imaging method that reduces distortions caused by breathing. During respiration, small movements of the chest and diaphragm can lead to subtle changes in the magnetic field within the head. These changes can introduce artifacts in certain MRI techniques, particularly susceptibility-weighted imaging (SWI), which is used to visualize veins, small hemorrhages, and iron deposits.\n\nThe investigated method measures breathing-related magnetic field variations during MRI acquisition using two very short navigator signals, referred to as free induction decay (FID) navigators. These signals are used to perform dynamic off-resonance correction during image reconstruction, reducing image blurring and distortion. The method does not increase scan time and does not affect standard clinical imaging.\n\nIn this study, patients scheduled for routine clinical brain MRI are asked to provide informed consent for use of their raw MRI data for research purposes. For each participant, two sets of SWI images are generated from the same acquisition: one using standard reconstruction and one using the free induction decay navigator-based dynamic off-resonance correction method (FID-DORK). The objective is to assess whether the corrected images provide improved image quality and diagnostic reliability.\n\nThe study includes adult patients undergoing routine clinical MRI at Karolinska University Hospital. Image quality is evaluated using both visual assessment by neuroradiologists and quantitative measures of image variation. No additional imaging procedures, contrast agents, or scan time are required. All research data are pseudonymized prior to analysis.\n\nThe hypothesis is that the dual free induction decay navigator-based correction method (FID-DORK) improves the diagnostic quality of high-resolution three-dimensional echo-planar imaging susceptibility-weighted imaging brain MRI by reducing breathing-related artifacts.",[399],"Brain Diseases","2026-01-29",{"date":380,"type":36},{"date":403,"type":20},"2026-01-05",{"date":405,"type":20},"2027-12-31",{"name":42,"class":43},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":44},"100613901","detection-of-brain-metastases-using-a-novel-gadolinium-weighted-mri-sequence-a-prospective-comparison-100613901","NCT07272616","Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison","A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases","GDW","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for clinical brain MRI with gadolinium contrast\n* Known or suspected brain metastases\n* Able to provide informed consent\n* Able to lie still for the duration of the MRI examination\n\nExclusion Criteria:\n\n* Contraindications to MRI\n* Known allergy or contraindication to gadolinium-based contrast agents\n* Renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnant or breastfeeding\n* Inability to comply with study procedures",{"count":123,"type":20},"This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel \"gadolinium-weighted\" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.",[418],"Brain Neoplasms",{"date":420,"type":36},"2026-01-30",{"date":422,"type":36},"2026-01-28",{"date":405,"type":20},{"name":42,"class":43},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":21,"phases":434,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":44},"100622474","the-diagnostic-accuracy-of-ankle-audiometry-performed-with-the-b250-for-superior-canal-dehiscence-syndrome-in-patients-affected-by-pulsatile-tinnitus-andor-autophony-disorders-100622474","NCT07384091","The Diagnostic Accuracy of Ankle Audiometry Performed With the B250 for Superior Canal Dehiscence Syndrome in Patients Affected by Pulsatile Tinnitus and\u002For Autophony Disorders","AA by B250","Inclusion Criteria:\n\n* Age between 18 and 64 years.\n* Patients with symptoms of autophony and\u002For pulsatile tinnitus either due to a confirmed diagnosis of SCDS or not due to SCDS.\n\nExclusion Criteria:\n\n* Severe sensorineural hearing.\n* Middle ear or ear canal pathologies.\n* Vulnerable patients.\n* Confirmed intolerance or contraindication for body (ankle) vibratory stimulation.\n* Anatomical body anomalies affecting normal testing procedure or interpretation of results.","64 Years",{"count":347,"type":20},[23],"The goal of this clinical trial is to learn if the ankle audiometry test performed with the B250 bone conduction transducer can identify patients with superior canal dehiscence syndrome from those without among subjects presenting with autophony (a hearing condition where you hear your own body sounds) and\u002For pulsatile tinnitus.\n\nThe main question it aims to answer:\n\n• Can ankle audiometry performed with B250 identify the condition of superior canal dehiscence syndrome among patients with autophony and\u002For pulsatile tinnitus, with a significance level of 80% and power level of 15%?\n\nStudy participants will undergo ankle audiometry testing with the B250 and the threshold in dB FL (at the ankle) for which the patient hears the sound in the target ear will be measured.",[437,438,439],"Superior Canal Dehiscence Syndrome","Autophony","Pulsatile Tinnitus",[441,442,443],"SCDS","Ankle audiometry","B250","2026-01-26",{"date":446,"type":36},"2026-02-03",{"date":448,"type":20},"2026-02-01",{"date":450,"type":20},"2026-12-31",{"name":42,"class":43},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":44},"100619685","triocol---the-study-of-continued-advanced-medical-therapy-or-colectomy-in-patients-with-ulcerative-colitis-100619685","NCT07347834","TRIOCOL - The Study of Continued Advanced Medical Therapy or Colectomy in Patients With Ulcerative Colitis","TRIOCOL","Inclusion Criteria:\n\n* Patients with UC with active disease\n* failed at least two lines of advanced medical therapies\n* are eligible for both continued AMT and colectomy\n\nExclusion Criteria:\n\n* diagnostic uncertainty\n* diagnosis of impaired cognitive function\n* non-domestic and non-English speaking",{"count":370,"type":20},"Ulcerative colitis is an inflammatory disease affecting the rectum and colon, most commonly presenting in late adolescence or early adulthood. The primary treatment approach is pharmacological. Over the past two decades, there has been significant progress in the development of so-called advanced medical therapies, and new drugs in this category continue to emerge. These medications are highly effective for many patients, but not for all. If the first advanced therapy fails or is not tolerated, patients may switch to a second, third, or subsequent drugs. Unfortunately, the likelihood of success decreases with each additional line of therapy.\n\nAn alternative is surgery, specifically colectomy, which is a potentially curative treatment but may have a major impact on the individual. The overall objective of the study is to evaluate quality of life, functional outcomes, and patient satisfaction among those who choose continued medical therapy, compared to those who undergo colectomy, after at least two failed advanced medical therapies. Before making their treatment decision and enrolling in the study, patients will receive standardized information about all treatment options from a gastroenterologist and a colorectal surgeon. The aim is that the results of this study will provide valuable insights to better guide future patients with ulcerative colitis in choosing between continued advanced medical therapy and surgery.",[462],"Ulcerative Colitis (UC)",[464,465,466,467,468],"Ulcerative colitis","Advanced medical therapy","Colectomy","Health related quality of life","Shared decision-making","2026-01-16",{"date":471,"type":36},"2026-01-21",{"date":473,"type":36},"2024-10-22",{"date":475,"type":20},"2038-12",{"name":42,"class":43},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":485,"conditions":486,"keywords":489,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":44},"100616462","delayed-cerebral-infarction-beyond-endoluminal-spasmolysis-and-induced-hypertension-100616462","NCT07305922","Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension","Decibel","Inclusion Criteria:\n\n* Adults 18 years or older\n* Critical care after subarachnoid haemorrhage\n* Aneurysm secured by surgical clipping or endovascular procedure\n* Suspected, emerging or established severe cerebral vasospasm\n\nExclusion Criteria:\n\n* Anticipated survival less than five days, as determined by treating clinician\n* Transcranial Doppler signal too weak\n* Pregnancy",{"count":184,"type":20},"An observational study of patients with emerging or established severe cerebral vasospasm after subarachnoid haemorrhage, employing multimodal neuromonitoring.",[487,488],"Subarachnoid Aneurysm Hemorrhage","Cerebral Vasospasm After Subarachnoid Hemorrhage",[490,491,492,493],"Transcranial Doppler","Endoluminal Spasmolysis","Induced Hypertension","Multimodal Neuromonitoring","2025-12-18",{"date":496,"type":36},"2025-12-26",{"date":498,"type":36},"2025-12-01",{"date":500,"type":20},"2030-12-31",{"name":42,"class":43},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":21,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":523,"leadSponsor":525,"locationsCount":44},"100615622","sentinel-node-resection-with-or-without-lecs-after-noncurative-esd-for-egc-100615622","NCT07295002","Sentinel Node Resection With or Without LECS After Noncurative ESD for EGC","COmpletion Sentinel Node Resection With or Without Minimally invAsive and Endoscopic Cooperative Surgery Following noncuRative Endoscopic Submucosal Dissection for Early Gastric Cancer","Co-SNARE","Inclusion Criteria:\n\n* EGC previously treated with ESD according to current guidelines (differentiated adenocarcinoma, not ulcerative, of any size, differentiated adenocarcinoma ulcerative \\\u003C\u002F=3cm, undifferentiated adenocarcinoma not ulcerative \\\u003C\u002F=2cm)\n* Non curative resection\n\n  * Lymphovascular invasion\n  * Non-radical resection vertical margin\n  * deep submucosal invasion\n* Signed informed consent\n\nExclusion Criteria:\n\n* Location within 2 cm from cardia or pylorus\n* Non-curative resection with only non-radicality horizontal margin\n* Inoperative because of severe comorbidities\n* Previous radiotherapy to the upper abdomen\n* Pregnancy\n* Allergy to ICG\n* Inability to provide informed consent due to cognitive impairment, language barrier, or other reasons impairing understanding and autonomous decision-making.",{"count":511,"type":20},10,[23],"For patients with non-curative resection after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC), complementary surgery is generally recommended. However, about 2\u002F3 of patients have no remaining tumor in the stomach or regional lymph nodes. In this trial, Indocyanine Green (ICG)-guided lymphadenectomy with or without laparoscopic and endoscopic cooperative surgery (LECS) will be tested as a less invasive alternative in such cases. For patients with a primary radically resected EGC, ICG-guided lymphadenectomy alone will be performed. For patients with deep-margin positive EGC, ICG-guided lymphadenectomy and LECS will be performed, in order to ensure both local tumor control in the stomach and in regional nodes.",[515],"Early Gastric Cancer",[517,518],"sentinel node-resection","minimal invasive surgery","2025-12-15",{"date":521,"type":36},"2025-12-19",{"date":280,"type":20},{"date":524,"type":20},"2029-10-01",{"name":42,"class":43},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":535,"conditions":536,"keywords":539,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":44},"100604449","immune-system-effects-in-children-born-to-women-with-multiple-sclerosis-treated-with-monoclonal-antibody-therapy-during-pregnancy-100604449","NCT07149662","Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy","B-cellspåverkan i Barn Till Kvinnor Med Multipel Skleros Och Rituximabbehandling före Eller Under Graviditeten (B-cell Effects in Children Born to Women With Multiple Sclerosis and Rituximab Treatment Before or During Pregnancy)","Inclusion Criteria:\n\n* Established multiple sclerosis diagnosis\n* Rituximab, ocrelizumab, ofatumumab or other monoclonal CD-20 antibody has been administered within 6 (12) months prior to or during pregnancy\n* Other immun modulation treatment has been administered within 6 (12) months prior to or during pregnancy\n* No treatment has been administered within 6 (12) months prior to or during pregnancy\n\nExclusion Criteria:\n\n\\- Previous stem cell transplantation",{"count":534,"type":20},111,"The goal of this observational study is to learn about consequences for the child when the mother is treated with rituximab (or other monoclonal CD-20 antibodies) before or during pregnancy. The main questions it aims to answer are:\n\n* Is the infant's immune system effected with lower levels of B-cell markers, higher rates of infections or poor vaccine response?\n* Are the monoclonal CD20-antibodies fully eliminated in women treated within 6 (12) months prior to conception?\n\nParticipants will:\n\n* At the time of clinical routine blood sampling (at the end of each trimester) the becoming mother will give some additional blood samples for analysis of drug concentration\n* Within the first year postpartum the child will leave a blood sample to detect antibodies induced by vaccination or infections\n* Within our routine contacts with the participant (mother) will be asked about infections in both the mother and the child",[537,538],"Multiple Sclerosis","Pregnancy",[537,540,541,542,543,538],"Rituximab","Ocrelizumab","Ofatumumab","monoclonal CD-20 antibodies","2025-11-20",{"date":546,"type":36},"2025-11-25",{"date":548,"type":20},"2026-02",{"date":550,"type":20},"2028-03",{"name":42,"class":43},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":560,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":21,"phases":563,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":581},"100607362","phase-3-recurrence-of-atrial-fibrillation-after-cardioversion-of-patients-randomized-to-dapagliflozin-or-usual-care-100607362","NCT07187570","RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care","RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care","RECUR-AF","Inclusion Criteria:\n\n* Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.\n* Age ≥ 55 years.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Current treatment with an SGLT2 inhibitor.\n* Prior\u002Fcurrent diagnosis of heart failure.\n* Type 1 diabetes mellitus.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin\u002F1.73m2.\n* Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).\n* Contraindications to SGLT2 inhibitors.\n* Any condition or circumstance in which the patient should not participate in the study according to the study investigator.","55 Years",{"count":562,"type":20},1600,[564],"PHASE3","The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:\n\n• Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?\n\nResearchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.\n\nPersons with atrial fibrillation who are planned for an electric cardioversion will:\n\n* Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days\n* Undergo a planned electric cardioversion of the atrial fibrillation\n* Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days",[567],"Atrial Fibrillation (AF)",[569,570,571,572],"dapagliflozin","sodium-glucose transport-2 inhibitor","electric cardioversion","hand-held ECG device","2025-09-18",{"date":575,"type":36},"2025-09-23",{"date":577,"type":36},"2025-06-03",{"date":579,"type":20},"2027-12",{"name":42,"class":43},7,{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":99,"sex":52,"minAge":53,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":44},"100606983","biomarkers-in-the-endometrial-fluid-tissue-and-follicular-fluid-of-moderatesevere-endometriosis-patients-100606983","NCT07182643","Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate\u002FSevere Endometriosis Patients","An Exploratory Study of Biomarkers in the Endometrial Fluid, Tissue, and Follicular Fluid of Moderate\u002FSevere Endometriosis Patients: a Prospective Study","Inclusion Criteria:\n\n* Age 18-40 years old\n* Diagnosed with moderate\u002Fsevere endometriosis by ultrasound or laparoscopy (patient group)\n* Regular menstrual cycles 28-35 days\n* Speak English or Swedish and agree to participate in the study\n\nExclusion Criteria:\n\n* Pregnancy or lactation in the last 3 months\n* Uterine anomalies\n* Pelvic inflammatory disease, endometritis, STD\n* Gynaecological cancers or other malignancies in the patient's history\n* Smoking (more than 10 cigarettes per day) or alcohol abuse\n* Immunosuppressing medicines\n* Major abdominal or pelvic surgery in the last 3 months\n* A specific genetic disease that is diagnosed before PGT in women undergoing treatment","40 Years",{"count":591,"type":20},90,"This study aims to explore biomarkers in the endometrial fluid and tissue of women with moderate to severe endometriosis, with a specific focus on those involved in pre-receptive endometrium and embryo implantation. This research has the potential to uncover diagnostic indicators of impaired pre-receptive endometrium, examine pathophysiological pathways, and identify future targets for therapeutic intervention. Ultimately, the findings may contribute to more personalized fertility treatments, offering new hope for women struggling with endometriosis-related infertility.",[214],[595,596,597,598,599],"endometriosis","biomarkers","implantation","infertility","fertility","2025-09-16",{"date":602,"type":36},"2025-09-19",{"date":604,"type":20},"2025-10-01",{"date":405,"type":20},{"name":42,"class":43},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":615,"targetDuration":4,"studyType":21,"phases":617,"briefSummary":618,"conditions":619,"keywords":620,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":633},"100604841","registry-based-optimization-of-therapy-in-heart-failure-100604841","NCT07154758","Registry BAsed Optimization Of Therapy in Heart Failure","Optimizing HF Treatment by Registry Screening for Need of Implementation and Referral to the Optimization Outpatient Clinic","REBOOT-HFrEF","Inclusion Criteria:\n\n* Registration in SwedeHF with an index date after January 1st 2023 for the screening arm. For controls, hospital access after January 1st 2023.\n* HF duration \\>6 months to ensure that patients had time to go through the treatment optimization process as recommended by the guidelines.\n* HF with reduced EF (HFrEF) defined as categorical or continuous EF ≤40%\n* Capable of giving signed informed consent (for the screening arm)\n\nExclusion Criteria:\n\n* Under optimization of HF therapy\n* In judgment of the investigator unlikely to understand or comply with study procedures\n\nControl population is sex and age matched with the SwedeHF screening arm (1:1)",{"count":616,"type":20},1000,[23],"Rationale. Although several pharmacological treatments, namely renin-angiotensin-system inhibitors, sacubitril\u002Fvalsartan, beta-blockers, mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors, improve mortality\u002Fmorbidity in heart failure with reduced ejection fraction (HFrEF), their use in clinical practice is still limited.\n\nAim. The aim of this project is to use the Swedish HF registry to identify HFrEF patients in need of 1) treatment implementation (initiation of treatments\u002Fuptitration), 2) screening and treatment of ID, and 3) with an indication for HF devices (CRT or ICD) but not implanted device, 4) referral for physiotherapy.\n\nOutcomes.\n\nPrimary outcome: number of participants experiencing at least one of the following:\n\n1. Drug initiation or uptitration (SGLT2i, MRA, BB, RASi, ARNi, iv iron)\n2. ID screening\n3. Referral for device therapy (CRT\u002FICD)\n\nSecondary outcome:\n\n1. Number of participants experiencing at least one drug initiation in the interventional vs. control arm.\n2. Number of participants experiencing at least one drug dose up-titration in the interventional vs. control arm.\n3. Number of participants experiencing referral for CRT or ICD in the interventional vs. control arm.\n4. Number of participants screened for iron deficiency in the interventional vs. control arm.\n\nTertiary outcome:\n\n1\\. Number of participants referred for physiotherapy in the interventional vs. control arm.\n\nStudy design. 500 patients will be screened through the Swedish Heart Failure Registry and, whether not on optimal medical treatment, implementation will be started. Outcome will be compared with a control population of 500 patients not enrolled in SwedeHF.",[317],[621,622,623,624],"Implementation","Guideline-directed medical therapy","registry","Swedish Heart Failure Registry","2025-08-26",{"date":627,"type":36},"2025-09-04",{"date":629,"type":36},"2024-05-01",{"date":631,"type":20},"2026-06-30",{"name":42,"class":43},6,{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":21,"phases":643,"briefSummary":644,"conditions":645,"keywords":647,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":44},"100540860","realmove-lung-assessing-tumour-motion-with-dynamic-mri-100540860","NCT06322329","RealMove (Lung): Assessing Tumour Motion With Dynamic MRI","RealMove(lung)","Inclusion Criteria:\n\n* Accepted for SBRT treatment of one or more caudally situated lung targets (NSCLC or metastases), i.e. below the carina.\n* Age ≥ 18 years\n* Adequate clinical condition to maintain immobilised position for at least 30 minutes\n* Adequate Swedish skills and cognitive function to understand study information and to fill in the questionnaire\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, or planned pregnancy or breastfeeding, during treatment\n* Contraindication for MRI examination\n* Otherwise incapable of participating in study",{"count":642,"type":20},150,[23],"The study aims to develop an improved method to tailor the geometric safety margin when treating with stereotactic body radiotherapy (SBRT), to avoid tumour cells being missed during irradiation and to limit the exposure of normal tissues as much as possible. Dynamic magnetic resonance imaging (MRI) is assumed to represent the tumour motion during the respiratory cycle more realistically, compared to 4-dimensional computed tomography (4D CT), thanks to its high temporal resolution and the possibility to image the motion over a longer period of time. Patients receiving SBRT for a pulmonary target located below the level of the carina are included in the study, and the hypothesis will be tested through a comparison of the tumour amplitude measured with each modality. Furthermore, the predictive value of the image series acquired at treatment planning, for the motion patterns observed at each treatment fraction, will be evaluated through repeated 4D CBCT acquisitions.",[646],"Lung Tumor",[648,649,650],"Radiotherapy","Motion management","Dynamic MRI","2025-08-25",{"date":653,"type":36},"2025-09-02",{"date":655,"type":36},"2024-03-15",{"date":657,"type":20},"2036-03-17",{"name":42,"class":43},""]